Cite
LBA2 Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysis.
MLA
Qin, S., et al. “LBA2 Tislelizumab (TIS) versus Sorafenib (SOR) in First-Line (1L) Treatment of Unresectable Hepatocellular Carcinoma (HCC): The RATIONALE-301 Chinese Subpopulation Analysis.” Annals of Oncology, vol. 33, Nov. 2022, pp. S1454–55. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.10.100.
APA
Qin, S., Guo, Y., Meng, Z., Wu, J., Gu, K., Zhang, T., Lin, X., Lin, H., Ying, J.-E., Zhou, F., Hsing-Tao, K., Chao, Y., Li, S., Chen, Y., Boisserie, F., Abdrashitov, R., & Bai, Y. (2022). LBA2 Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysis. Annals of Oncology, 33, S1454–S1455. https://doi.org/10.1016/j.annonc.2022.10.100
Chicago
Qin, S., Y. Guo, Z. Meng, J. Wu, K. Gu, T. Zhang, X. Lin, et al. 2022. “LBA2 Tislelizumab (TIS) versus Sorafenib (SOR) in First-Line (1L) Treatment of Unresectable Hepatocellular Carcinoma (HCC): The RATIONALE-301 Chinese Subpopulation Analysis.” Annals of Oncology 33 (November): S1454–55. doi:10.1016/j.annonc.2022.10.100.